Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Medicine (Baltimore) ; 103(19): e38110, 2024 May 10.
Article En | MEDLINE | ID: mdl-38728478

RATIONAL: The Philadelphia chromosome (Ph) is seen in most patients with chronic myeloid leukemia and some patients with acute lymphoblastic leukemia. However, Ph-positive acute myeloid leukemia (Ph + AML) is a rare entity with a poor prognosis and a short median survival period. To date, there have been few clinical reports on this disease. And the treatment regimen of this disease has not been uniformly determined. PATIENT CONCERNS: We report a case of a Ph + AML. A 32-year-old male who was admitted to our hospital with weakness for 2 months. DIAGNOSIS: Philadelphia chromosome-positive acute myeloid leukemia. INTERVENTIONS: The patient achieved complete remission by the administration of a tyrosine kinase inhibitor, combined with low-intensity chemotherapy and a B-cell lymphoma 2 inhibitor. Then, allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his sister was successfully performed. OUTCOMES: The patient has been in a continuous remission state for 6 months after transplantation. LESSONS: We reported a rare Ph + AML case, successfully treated with allo-HSCT. This case provided strong support for treating Ph + AML with allo-HSCT.


Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute , Philadelphia Chromosome , Humans , Male , Hematopoietic Stem Cell Transplantation/methods , Adult , Leukemia, Myeloid, Acute/therapy , Leukemia, Myeloid, Acute/genetics , Transplantation, Homologous , Remission Induction
2.
Medicine (Baltimore) ; 102(5): e32816, 2023 Feb 03.
Article En | MEDLINE | ID: mdl-36749229

RATIONALE: Activated phosphoinositide 3-kinase δ syndrome (APDS), a recently described primary immunodeficiency,is caused by autosomal dominant mutation in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta(PIK3CD) gene encoding the p110δ catalytic subunit of PI3Kδ (APDS1) or the PIK3R1 gene that encodes the p85α regulatory subunit of PI3Kδ (APDS2). Gain-of-function mutation of PIK3CD in APDS1 leads to p110δ hyperactivity, with the result of the hyperphosphorylation of downstream mediators of Akt and mammalian target of rapamycin that cause a series of clinical symptoms. Few cases with APDS were reported in Asia. PATIENT CONCERNS: We report a 6-year-old patient with a recurrent respiratory infection, cryptosporidium enteritis, lymphoproliferation, high serum immunoglobulin-M level, anemia, and inverted CD4+/CD8+ ratio. The whole exome sequencing confirmed a heterozygous missense mutation c.3061G>A(p.E1021K)in patient and her mother. Her mutant gene is inherited from her mother, but her mother has not any clinical symptoms. DIAGNOSES: Activated phosphoinositide 3-kinase δ syndrome. INTERVENTIONS: The patient was received immunoglobulin (Ig) replacement therapy, antibiotics, and rapamycin treatment. Through effectively controlling infection and optimal timing of transplantation by adjusting the conditioning regimen, haploidentical Hematopoietic Stem Cell Transplantation(haplo-HSCT) from her brother was successfully performed. OUTCOMES: The patient is in good condiion with a good quality of life after 20 months of follow-up. LESSONS: We reported a rare APDS1 case with PIK3CD E1021K gene mutation, Successfully treated with haplo-HSCT. This case provided a reference for treating APDS with haplo-HSCT.


Cryptosporidiosis , Cryptosporidium , Hematopoietic Stem Cell Transplantation , Immunologic Deficiency Syndromes , Primary Immunodeficiency Diseases , Child , Female , Humans , Male , Class I Phosphatidylinositol 3-Kinases/genetics , Cryptosporidiosis/drug therapy , Immunologic Deficiency Syndromes/genetics , Mutation , Phosphatidylinositol 3-Kinase , Phosphatidylinositol 3-Kinases/genetics , Quality of Life , Sirolimus/therapeutic use
...